World Hepatitis Day 2025: Top 10 countries account for two-thirds of the global hepatitis B and C cases, with China and India leading
It is one of the leading causes of death globally—with an estimated 1.3 million people dying in 2022 from the disease, according to the World Health Organisation (WHO) report.
Notably, the top ten countries in the world account for nearly two-thirds of the global burden of viral hepatitis B and C combined, according to the report.
For hepatitis B, the top three countries—China, India, and Indonesia—represent 50% of the global burden in 2022; and for hepatitis C, six countries—China, India, Indonesia, Pakistan, the Russian Federation, and the United States of America—represent 50% of the global burden, the report highlighted.
Since 2015, there have been certain significant advancements forward in testing and treatment for viral hepatitis, with it being more widely available.
While countries worldwide have national strategies and updated clinical guidelines to facilitate people getting prevention, testing, and treatment services; however, overall global coverage lacks and remains unchanged; its implementation continues to proceed incredibly slowly, making progress critical to the global response.
As a result, the world observes World Hepatitis Day on 28th July every year to promote global awareness of hepatitis prevention, early detection, and effective treatment options.
Source: Global Hepatitis Report 2024, World Health Organisation
India is one of the countries with the highest burden of viral hepatitis with the data revealing a significant burden of hepatitis infections with the country accounts for 29,800,000 total hepatitis B infections and 5,500,000 total hepatitis C infections across all ages.
When combined, these results highlight 35,300,000 total hepatitis B and hepatitis C infections, representing 11.6% of the total combined hepatitis B and C infections across the countries, making India the second-highest contributor after China.
Cherry Gupta is an Assistant Manager - Content at The Indian Express. She is responsible for crafting compelling narratives, uncovering the latest news and developments, and driving engaging content based on data and trends to boost website traffic and audience engagement. One can connect with her on LinkedIn or by mail at cherry.gupta@indianexpress.com. ... Read More
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
23 minutes ago
- Hindustan Times
Why childhood vaccines matter: Paediatrician raises concern on the alarming decline in global vaccine coverage
Most parents in India follow the vaccination schedule because it's part of growing up. But beyond that routine lies a worrying trend. Global childhood immunisation, which once saw steady progress, is now slowing, and millions of children remain vulnerable to diseases we thought were under control. According to a 2025 update by the WHO and Unicef, 14.3 million infants worldwide received no vaccines at all last year, while another 20 million missed at least one critical dose of the DTP vaccine, which protects against diphtheria, tetanus, and pertussis. Childhood should be protected, not paused. Vaccines help make that possible.(Adobe Stock) In clinical practice, this is more than data—it's visible in children who arrive with infections that could have been avoided, and in communities dealing with outbreaks that spread simply because protection levels dropped. Dr Vignatha Sajja, Consultant Paediatrician, Arete Hospitals, shares with Health Shots, five essential reasons why timely childhood vaccination matter more than ever: 1. Protection when the body is still learning The first five years of life are biologically fragile. A young child's immune system is still developing and doesn't yet know how to fight many infections. That's where vaccines step in—offering essential protection before natural defences mature. Diseases like measles, diphtheria, and polio don't give you time to prepare. They strike quickly, and in unvaccinated children, can cause complications that leave lasting damage, or worse. Global immunisation programs, such as the Expanded Programme on Immunisation (EPI), have prevented over 150 million child deaths since 1974. The numbers speak for themselves. 2. Building a safety net for all Vaccines work best when most people get them. When a large part of the population—about 95%—is immunised, it creates a buffer that protects even those who aren't vaccinated, such as newborns or children undergoing medical treatments. When enough children in a community are vaccinated, it creates a protective barrier that slows the spread of disease,even to those who aren't immunised. Herd immunity is effective only when a sufficient number of children are vaccinated. But measles shots have been slipping through the cracks. In 2024, only 84% of children worldwide received protection, far short of the mark needed to prevent outbreaks. As a result, measles made a comeback in over 60 countries, even in places where it hadn't shown up in years. 3. Reducing health inequity Children who miss vaccines aren't always in far-off regions. Even in India, access to routine immunisation depends heavily on geography and infrastructure. Children in urban slums, tribal belts, or conflict-affected areas often fall through the cracks. That's why national efforts like Mission Indradhanush were launched—to reach the last-mile child in India. When parents everywhere ensure their children are vaccinated, it not only protects their homes but also helps reduce the health gap between rural and urban India. 4. Avoiding preventable costs Beyond health, the cost of vaccine-preventable diseases can be high—hospital bills, lost workdays, and slow recoveries take their toll. In the US, regular childhood vaccines are estimated to have saved over $2.7 trillion in societal costs. The figures may differ in India, but the message is clear: stopping disease before it starts is always the wiser investment. 5. Fighting misinformation with awareness The internet is full of misleading claims—some sounding all too credible. Worries about vaccine safety, doubts over their need, or fear of side effects can cause parents to delay or miss doses. However, even brief delays can allow disease to take hold. Vaccines undergo years of rigorous testing and are supported by real-world evidence. Today, the greater risk isn't from the vaccine—it's from the disease waiting on the other side of hesitation. What can parents do? Stick to the national immunisation schedule. Delays reduce effectiveness and increase risk. Maintain a vaccination card or record. This helps track doses and is often required during emergencies or travel. Speak to your paediatrician. Whether you have doubts or missed a shot, an honest conversation helps. Check requirements if relocating. Different regions may carry different disease risks—stay informed. Vaccination is one of the simplest, most powerful ways to secure your child's health. It's not just about disease prevention—it's about giving children the freedom to grow, play, and learn without fear.
Hindustan Times
6 hours ago
- Hindustan Times
Health Talk: Taking the road to hepatitis elimination
The International Agency for Research on Cancer (IARC) recently classified hepatitis D as carcinogenic—cancer-causing—to humans, just like hepatitis B and C. Hepatitis D, which only affects individuals infected with hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone, it added. (AP/ Representative photo) Hepatitis D, which only affects individuals infected with hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone, it added. Viral hepatitis – types A, B, C, D, and E – are major causes of acute liver infection. Among these, only hepatitis B, C, and D can lead to chronic infections that significantly increase the risk of cirrhosis, liver failure, or liver cancer. Each year, July 28 is observed as World Hepatitis Day, as viral hepatitis continues to remain a serious public health threat and one of the primary causes of liver cancer. Yet most people with hepatitis don't know they're infected, says the World Health Organization (WHO). According to the UN health body, types B, C, and D affect at least 300 million people globally and cause at least 1.3 million deaths each year, mainly from liver cirrhosis and cancer. In a paper published on Monday, The Lancet Commission also mentioned that three in five liver cancer cases happen due to preventable risk factors, including fatty liver, alcohol, and viral hepatitis. It also added that obesity-linked cancer cases are on the rise. The majority of liver cancer cases can be prevented by reducing levels of viral hepatitis, alcohol consumption, and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), it said. Liver cancer is already a major cause of death and disability. Globally, it's the sixth most common cancer and the third leading cause of death from cancer. Interestingly, the Commission estimated in the paper that at least 60% of liver cancers are preventable via control of modifiable risk factors, including hepatitis B virus (HBV), hepatitis C virus (HCV), MASLD, and alcohol. While there are preventive measures and treatment available to combat this public health threat, last year's Global Hepatitis Report underscored some challenges that majorly impact disease management. According to the report, testing and treatment coverage remain critically low: only 13% of people with hepatitis B and 36% with hepatitis C had been diagnosed by 2022. Treatment rates were even lower – 3% for hepatitis B and 20% for hepatitis C – well below the 2025 targets of 60% diagnosed and 50% treated. Integration of hepatitis services remained uneven: 80 countries have incorporated hepatitis services into primary health care, 128 into HIV programmes, and just 27 have integrated hepatitis C services into harm reduction centres. The next challenge, according to the report, will be to scale up the implementation of prevention, testing, and treatment coverage. Achieving WHO's 2030 targets could save 2.8 million lives and prevent 9.8 million new infections. With declining donor support, countries must prioritize domestic investment, integrated services, better data, affordable medicines, and ending stigma, said experts in the report. 'Every 30 seconds, someone dies from a hepatitis-related severe liver disease or liver cancer. Yet we have the tools to stop hepatitis,' WHO director-general Tedros Adhanom Ghebreyesus said in a statement on World Hepatitis Day. He is right. We have the tools at our disposal; all we need is for stakeholders—governments, civil society, community leaders, etc.—to come together, to jointly work towards eliminating hepatitis.
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
India launches formal rules to fix, streamline drug and device clearances
India has released its first official set of guidelines on how expert panels should review and approve new drugs, medical devices, and biologics, Mint reported. This move is aimed at fixing problems of unclear and inconsistent approvals that have previously slowed down drug launches and weakened the pharmaceutical industry's trust in the system. These new rules, issued by the Central Drugs Standard Control Organisation (CDSCO), are designed to improve how India regulates new medical products. The goal is to make the approval process quicker, more transparent, and predictable, the news report said. The guidelines define how Subject Expert Committees (SECs) should be formed, how experts are chosen, and how they must review applications. These SECs play a key role in advising the Drugs Controller General of India (DCGI) on whether a product should be approved. The overhaul follows recommendations from the World Health Organisation (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organisation. The WHO called for stronger transparency and data integrity to align India's system with global standards. Why this is important for India's pharma sector? India's pharmaceutical industry is the world's third-largest by volume and 14th by value. It supplies around 20 per cent of the global generic drug demand and manufactures over 60,000 products across 60 therapy areas. The sector includes generic medicines, vaccines, biologics, over-the-counter drugs, and more. In its review, the WHO had asked Indian authorities to better track low-quality or fake medical products, start a market monitoring programme, and ensure drug advertisements are not misleading. Many of these suggestions are now being followed by the DCGI and those involved in SEC meetings, the news report said. Stricter criteria and structured evaluations Each SEC has eight members — one pharmacologist and seven other experts from research or medical fields. At least four members must be present to make a decision. Earlier, the lack of formal rules often led to delays and confusion in the approval process. Now, SEC members must meet strict criteria, such as having at least 10 published research papers and a 2:1 citation ratio. They are appointed for three years and must follow rules on confidentiality, impartiality, and attendance. Those who miss meetings without good reason can be removed. The new document also says SECs must evaluate drug safety, effectiveness, and risks using strong scientific standards. Decisions like clinical trial waivers must be clearly justified, and discussions must only focus on scientific and regulatory issues — not pricing or business concerns, Mint reported. US hits Indian exports with blanket 25% tariffs The US government has decided to impose a 25 per cent tariff on all Indian exports starting August 7 — without any exemptions. This new order removes earlier tariff breaks given to products like pharmaceuticals, electronics, and energy goods. GTRI founder Ajay Srivastava said this is one of the toughest trade measures by the US against India, news agency PTI reported. India's top export items to the US — like smartphones ($10.9 billion), petroleum products ($4.1 billion), and pharmaceuticals ($9.8 billion) — will be hit hardest. Srivastava said these sectors have high import content and low local value addition, making them vulnerable to the tariff hike. USFDA actions slow down Indian drug approvals Meanwhile, Indian drugmakers are also facing regulatory challenges abroad. In the first quarter of FY25, the US Food and Drug Administration (USFDA) sharply reduced the number of abbreviated new drug application (ANDA) approvals for Indian firms, according to a report by The Times of India. Companies like Cipla, Sun Pharma, Dr Reddy's, Lupin, and Aurobindo Pharma are under increased inspection. Aurobindo's approvals dropped due to issues at its Unit III plant. In May, the company got seven observations from the USFDA at its Bhiwadi facility and earlier three more for its Andhra Pradesh site. Cipla also got six observations for its Goa plant in June. In a filing, the company said it was committed to addressing the concerns in time. A Business Standard report said that the USFDA's Centre for Drug Evaluation and Research recently found that 11 per cent of Indian drug manufacturing facilities had violations, including data integrity issues.
